

**2018 Mo-99 TOPICAL MEETING ON
MOLYBDENUM-99 PRODUCTION TECHNOLOGY DEVELOPMENT**

**SEPTEMBER 23-26, 2018
HILTON KNOXVILLE HOTEL
KNOXVILLE, TN**

**Northwest Medical Isotopes, LLC Project
Overview and Status**

Carolyn C. Haass
Northwest Medical Isotopes, LLC
815 NW 9th Ave, Suite 256, Corvallis, OR 97330, USA

ABSTRACT (12 PT, BOLD, ALL CAPS)

Northwest Medical Isotopes, LLC (NWMI) has received their Construction Permit from the U.S. Nuclear Regulatory Commission and is currently completing the final design and Operating License Application for a new radioisotope production facility (RPF) in Columbia, Missouri. The RPF is designed with an anticipated capacity of 3500 six-day Curies of Mo-99 per week, this new facility will contribute significantly to increased reliability of Mo-99 supply globally. In addition, NWMI will use existing network of University Reactors for the irradiation of our LEU targets. In addition, R&D testing over the last 18 months has demonstrated that our LEU target material and configuration can be irradiated and then processed to produce significant quantities of Mo-99. The RPF has been designed to maximize production at peak demand times. This allows Mo-99 supply to best match customer requirements at the peak times in the week when it is required. In doing this, decay and therefore waste are both reduced. Key features of the new plant are LEU technology, utilization of proven Mo-99 production technology and effective waste and environmental emissions control. An overview of the project and current status will be presented.